TendoNova welcomes Mark Samuels as new CEO

– USA, GA –  TendoNova Corporation today announced the appointment of Mark Samuels as CEO, effective September 9th, 2020.

Mr. Samuels is an experienced Atlanta-based entrepreneur and business leader with a proven track record and multiple successful exits in the medical device industry. TendoNova is an Atlanta-based medical device company that develops devices that enable micro-invasive orthopedic procedures. Its initial product, the Ocelot™ System, addresses chronic tendon pain, a prevalent condition in both athletes and the population at large.

“It is with great pleasure that we welcome Mark Samuels as our new CEO. With the addition of his extensive experience in the medical device industry, to the investment and support of the National Football League Players Association, we believe the Company has all the components needed to drive success,” said Board Chairman, Lou Malice.

About Mark Samuels

Before joining TendoNova, Mr. Samuels was CEO of OBMedical Company for two and a half years. Under his leadership, OBMedical resolved technical and financial issues that had delayed its product launch and grew sales of its advanced fetal monitoring system for women in labor and their babies. Mr. Samuels engineered the sale of OBMedical Company to Philips Medical in 2018 for an undisclosed sum and acted as General Manager for the company until 2019.

“I am very excited for the opportunity to join the TendoNova team. The Ocelot technology has the potential to improve tendon treatment worldwide,” said new CEO, Mark Samuels. “My discussions with potential patients and physicians show a compelling need for improved tendon pain treatment. The Ocelot™ can help meet this need by improving accessibility and physician effectiveness in tendon procedures.”

Founded in 2017, TendoNova combines decades of regenerative medicine know-how with modern data analytics to enable in-office procedures to treat chronic tendon pain. The Ocelot System encourages the growth of a healthy tendon to replace painful lesions by performing a controlled mechanical debridement of a targeted area. Current methods of treating chronic tendon pain, such as using a needle to poke holes in a tendon, rely heavily on clinician skill and are expensive, invasive, or have inconsistent outcomes. This leaves patients and physicians with limited viable treatment options for patients that fail to heal. TendoNova’s Ocelot System is a smart tool that is easy to use, cost-effective, and provides real-time data that enhances the clinician’s skill. By making treatment of chronic tendon pain more accessible and reliable, TendoNova’s Ocelot System brings surgical level care to the office and training room.

About TendoNova

Founded in 2017, TendoNova is a medical device company whose initial product is the Ocelot System, a patented, cutting-edge device and digital health solution that brings surgical level care to the physician’s office. Designed to treat chronic tendon pains such as tennis elbow and plantar fasciitis, the Ocelot System promises to lower both the recovery time and patient cost by bringing a proven treatment methodology into the physician’s office setting.

For more information: https://www.tendonova.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team